Dx & Vx Co., Ltd. (KOSDAQ:180400)
2,380.00
+30.00 (1.28%)
At close: Sep 11, 2026
Dx & Vx Revenue
Dx & Vx had revenue of 6.40B KRW in the quarter ending June 30, 2026, a decrease of -26.08%. This brings the company's revenue in the last twelve months to 26.22B, down -15.72% year-over-year. In the year 2025, Dx & Vx had annual revenue of 29.36B, down -13.52%.
Revenue (ttm)
26.22B
Revenue Growth
-15.72%
P/S Ratio
8.93
Revenue / Employee
n/a
Employees
n/a
Market Cap
234.26B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.36B | -4.59B | -13.52% |
| Dec 31, 2024 | 33.95B | -7.30B | -17.69% |
| Dec 31, 2023 | 41.24B | 9.06B | 28.15% |
| Dec 31, 2022 | 32.18B | 24.71B | 330.83% |
| Dec 31, 2021 | 7.47B | -226.13M | -2.94% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Medical Science | 102.16B |
| Seoulin Bioscience | 83.17B |
| Cytogen | 27.38B |
| Protia | 17.75B |
| HLB Panagene | 14.71B |
| 3billion | 11.71B |
| GENINUS | 11.28B |
| Median Diagnostics | 7.86B |